Trademark: 79330538
Word
BERGENBIO
Status
Registered
Status Code
700
Status Date
Tuesday, August 1, 2023
Serial Number
79330538
Registration Number
7123344
Registration Date
Tuesday, August 1, 2023
Mark Type
3000
Filing Date
Friday, October 22, 2021
Published for Opposition
Tuesday, May 16, 2023

Trademark Owner History
BerGenBio ASA - Original Registrant

Classifications
5 Drugs and pharmaceutical products for medical purposes, namely, medications for the treatment of cancer and severe respiratory infections; drugs and pharmaceutical products for medical purposes incorporating antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors, or selective inhibitors of cell surface proteins, namely, medications for the treatment of cancer and severe respiratory infections; drugs and pharmaceutical products for medical purposes, for use in oncology and for the treatment of cancers, lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; drugs and pharmaceutical products that target axl, akt3 or other genes, proteins, kinases and enzymes; chemical preparations, chemical compounds, biochemical preparations and biologic compounds for medical purposes; diagnostic test kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for medical laboratory analysis; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease testing, namely, the testing for lung cancer, leukaemia, aggressive cancers, immune evasive cancers, metastatic cancers and severe respiratory infections; antibodies, small molecules and proteins for medical purposes; antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins for medical purposes; protein synthesis inhibitors for medical purposes
1 Chemical preparations, chemical compounds, biochemical preparations and biologic compounds for scientific or industrial purposes, or for use in laboratories or in research; chemical preparations, chemical compounds, biochemical preparations and biologic compounds for analytical and diagnostic purposes in laboratory use; chemical preparations, chemical compounds, biochemical preparations and biologic compounds for the experimental production of drugs, pharmaceutical products and biotechnological preparations; chemical preparations, chemical compounds, biochemical preparations and biologic compounds for use in the development and manufacture of diagnostic products and services, drugs and pharmaceutical products, namely, the diagnosis and treatment of cancers, including lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; chemical preparations, chemical compounds, biochemical preparations and biologic compounds for use in the development and manufacture of drugs and pharmaceutical products, namely, drugs and pharmaceutical products that target axl, akt3 or other genes, proteins, kinases and enzymes; active chemical and biochemical ingredients and components for use in the development and manufacture of diagnostic products and services, drugs and pharmaceutical products, namely, for the diagnosis and treatment of cancers, including lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; antibodies, small molecules and proteins for scientific or industrial purposes, or for use in laboratories or in research; antibodies, small molecules and proteins for use in the development and manufacture of diagnostic products and services, drugs and pharmaceutical products, namely, for the diagnosis and treatment of cancers, including lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; antibodies, small molecules and proteins for use in the development and manufacture of drugs and pharmaceutical products, namely, drugs and pharmaceutical products that target axl, akt3 or other genes, proteins, kinases and enzymes; antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins for scientific or industrial purposes, or for use in laboratories or in research; antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins for use in the development and manufacture of diagnostic products and services, drugs and pharmaceutical products, namely, for the diagnosis and treatment of cancers, including lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins for use in the development and manufacture of drugs and pharmaceutical products, namely, drugs and pharmaceutical products that target axl, akt3 or other genes, proteins, kinases and enzymes; proteins for use in kinase inhibiting technology, for scientific purposes
42 Drug discovery and pharmaceutical drug development services; scientific research services; research and development services in the fields of oncology and immunology; scientific research services related to the role of axl and related kinase signalling in disease; scientific research services related to axl biology and its role in mediating aggressive disease; scientific research services related to biomarker discovery; scientific research services related to the development of diagnostic products and services, in the field of treatment of cancers, including lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; scientific research services related to improving the efficacy of chemotherapy, targeted cancer therapy and immunooncology drugs; research and development services in the field of antibodies, small molecules and proteins; conducting and providing research and development services for others in the field of antibody and small molecule technology; medical and biotechnology research services; research, development and engineering of antibodies, small molecules and proteins, namely, anti-axl antibodies, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins; laboratory research services relating to the production of antibodies, small molecules and proteins, namely, anti-axl antibodies, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins; researching and developing the use of antibodies, small molecules and proteins for the treatment of patients; information, consultancy and advisory services related to the aforesaid services
The mark consists of the stylized wording "BERGENBIO" to the right of a design of 6 shaded circles and one outlined hexagon arranged in an overall hexagonal shape.

Trademark Events
Nov 21, 2023
Final Decision Transaction Processed By Ib
Nov 1, 2023
Final Disposition Notice Sent To Ib
Nov 1, 2023
Final Disposition Processed
Nov 1, 2023
Final Disposition Notice Created, To Be Sent To Ib
Aug 1, 2023
Notice Of Registration Confirmation Emailed
Aug 1, 2023
Registered-Principal Register
Jun 25, 2023
Notification Of Possible Opposition - Processed By Ib
Jun 7, 2023
Notification Of Possible Opposition Sent To Ib
Jun 7, 2023
Notification Of Possible Opposition Created, To Be Sent To Ib
May 17, 2023
Notification Processed By Ib
May 16, 2023
Official Gazette Publication Confirmation E-Mailed
May 16, 2023
Published For Opposition
Apr 26, 2023
Notification Of Possible Opposition Sent To Ib
Apr 26, 2023
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Apr 26, 2023
Notification Of Notice Of Publication E-Mailed
Apr 10, 2023
Approved For Pub - Principal Register
Apr 5, 2023
Teas/Email Correspondence Entered
Apr 5, 2023
Correspondence Received In Law Office
Apr 5, 2023
Teas Response To Office Action Received
Mar 28, 2023
Applicant/Correspondence Changes (Non-Responsive) Entered
Mar 28, 2023
Teas Change Of Correspondence Received
Mar 28, 2023
Attorney/Dom.Rep.Revoked And/Or Appointed
Mar 28, 2023
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Mar 28, 2023
Teas Change Of Owner Address Received
Feb 28, 2023
Notification Of Non-Final Action E-Mailed
Feb 28, 2023
Non-Final Action E-Mailed
Feb 28, 2023
Non-Final Action Written
Feb 5, 2023
Change Of Name/Address Rec'd From Ib
Jan 26, 2023
Teas/Email Correspondence Entered
Jan 26, 2023
Correspondence Received In Law Office
Jan 26, 2023
Teas Response To Office Action Received
Jan 24, 2023
Refusal Processed By Ib
Jan 4, 2023
Non-Final Action Mailed - Refusal Sent To Ib
Jan 4, 2023
Refusal Processed By Mpu
Oct 18, 2022
Non-Final Action (Ib Refusal) Prepared For Review
Oct 17, 2022
Non-Final Action Written
Oct 11, 2022
Non-Final Action (Ib Refusal) Withdrawn For Review
Oct 11, 2022
Applicant/Correspondence Changes (Non-Responsive) Entered
Oct 11, 2022
Teas Change Of Correspondence Received
Oct 11, 2022
Attorney/Dom.Rep.Revoked And/Or Appointed
Oct 11, 2022
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Oct 11, 2022
Teas Change Of Owner Address Received
Aug 9, 2022
Non-Final Action (Ib Refusal) Prepared For Review
Aug 8, 2022
Non-Final Action Written
Aug 1, 2022
Assigned To Examiner
May 17, 2022
Applicant/Correspondence Changes (Non-Responsive) Entered
May 17, 2022
Teas Change Of Correspondence Received
May 17, 2022
Attorney/Dom.Rep.Revoked And/Or Appointed
May 17, 2022
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
May 17, 2022
Teas Change Of Owner Address Received
Mar 5, 2022
New Representative At Ib Received
Jan 11, 2022
Application Filing Receipt Mailed
Jan 7, 2022
New Application Office Supplied Data Entered
Jan 6, 2022
Sn Assigned For Sect 66a Appl From Ib

Trademark Alertz updated from USPTO on 2030-01-24